Cita APA

Muggeri, A., Vago, M., Perez, S. E., Rubio, M., González, C., Magariños, C., . . . Perez Lloret, S. (2017). A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m2 (Dralitem® vs. Temodal® Capsules) in Patients with Primary Tumors of the Central Nervous System Under Fasting Conditions. Web

Citación estilo Chicago

Muggeri, Alejandro, Miguel Vago, Sebastian Ezequiel Perez, Marcelo Rubio, Cecilia González, Cristian Magariños, Mónica Rosenberg, Fernando Costa, and Santiago Perez Lloret. A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m2 (Dralitem® Vs. Temodal® Capsules) in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions. 2017.

Cita MLA

Muggeri, Alejandro, et al. A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m2 (Dralitem® Vs. Temodal® Capsules) in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions. 2017.